

Chinese Journal of Pharmacovigilance ›› 2024, Vol. 21 ›› Issue (7): 805-810.
DOI: 10.19803/j.1672-8629.20240208
Previous Articles Next Articles
LIU Yan1,2, AN Jing1, JIAO Yongzhuo1, LIANG Xuefeng1, ZHANG Xiaoshu1,2,*
Received:2024-02-04
Online:2024-07-15
Published:2024-07-31
CLC Number:
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu. Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
| [1] HÜBSCHEN JM, GOUANDJIKA-VASILACHE I. Measles[J]. The Lancet, 2022, 399(10325): 678-690. [2] VARICELLA C.In epidemiology and prevention of vaccine-preventable diseases[M]. Atlanta: CDC, 2021. [3] GASTAÑADUY PA, GOODSON JL, PANAGIOTAKOPOULOS L, et al. Measles in the 21st century: progress toward achieving and sustaining elimination[J]. Journal of Infectious Diseases, 2021, 224(Suppl4): S420-S428. [4] Chinese Preventive Medicine Association. Expert consensus on informed consent for vaccination (Part 1)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2021, 42(2): 181-210. [5] WHO. Global Measles and Rubella Strategic Plan 2012-2020 World[EB/OL]. [2024-04-19]. https://www.afro.who.int/publications/global-measles-and-rubella-strategic-plan-2012-2020. [6] WHO. Measles[EB/OL]. [2024-04-19]. http://www.who.int/news-room/facts-in-pictures/detail/measles. [7] GLYNN-ROBINSON A, KNAPP J, DURRHEIM D.How Australia’s measles control activities have catalyzed rubella elimination[J]. International Society for Infectious Diseases, 2021, 114: 72-78. [8] KAUFFMANN F, HEFFERNAN C, MEURICE F, et al.Measles, mumps, rubella prevention: how can we do better?[J]. Expert Review of Vaccines, 2021(2): 1-17. [9] MINTA AA, FERRARI M, ANTONI S, et al.Progress toward measles elimination - worldwide, 2000-2022[J]. Morb Mortal Wkly Rep, 2023, 72(46): 1262-1268. [10] OU AC, ZIMMERMAN LA, ALEXANDER JP, et al.Progress toward rubella and congenital rubella syndrome elimination - worldwide, 2012-2022[J]. Morb Mortal Wkly Rep, 2024, 73(8): 162-167. [11] PRYMULA R, POVEY M, BRZOSTEK J, et al.Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: results from five East European countries[J].Vaccine, 2021, 39(19): 2643-2651. [12] KUTER BJ, MARSHALL GS, FERGIE J, et al.Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R(II)[J]. Hum Vaccin Immunother, 2021, 17(12): 5372-5383. [13] LIU CG, LIANG GS, XU CQ.Advances in evaluation methods for vaccine risk-benefit assessment at home and abroad[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(11): 1097-1100. [14] HE Q, XU Y, LI YL, et al.Investigation on antibody levels of measles, rubella and mumps in healthy population in Guangzhou in 2020[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2023, 29(4): 392-396. [15] YU WZ, LIU LJ, XU CS, et al.Since the 18th National Congress of the Communist Party of China, China’s immunization program has promoted the people’s health protection[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2022, 28(5): 491-495. [16] LIU L, TANG FY, WANG ZG, et al.Incidence of adverse reactions to the combined live attenuated MMR vaccine after implementing the 2-dose immunization strategy in Jiangsu province, 2019-2021[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2022, 28(6): 695-698. [17] VESTERGAARD M, HVIID A, MADSEN KM, et al.MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis[J]. JAMA, 2004, 292(3): 351-357. [18] PKLEIN N, FIREMAN B, YIH W, et al.Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures[J]. Pediatrics, 2010, 126(1): e1-e8. [19] HABIB MDA, POVEY M, CASABONA G, et al.Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines[J]. Human Vaccines & Immunotherapeutics, 2023, 19(1): 2188852. [20] The Neurology Group, the Society of Pediatrics, Chinese Medical Association. Expert consensus on diagnosis, treatment and management of febrile seizures (2017 practical edition)[J]. Chinese Journal of Applied Clinical Pediatrics(中华实用儿科临床杂志), 2017, 32(18): 1379-1382. [21] GSBOS. Gansu Development Yearbook[EB/OL].[2024-07-04].https://tjj.gansu.gov.cn/tjj/c109464/info_disp.shtml. [22] SCQIM/FS AAP. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures[J]. Pediatrics, 2008, 121(6): 1281-1286. [23] DENG L, WOOD N, MACARTNEY K, et al.Developmental outcomes following vaccine-proximate febrile seizures in children[J]. Neurology, 2020, 95(3): e226-e238. [24] HUPPERTZ HI, FÜR INFEKTIONSKRANKHEITEN K, FÜR KINDER IDDA. Recommendations on the approach when unusual neurological symptoms occur in temporal association with vaccinations in childhood and adolescence[J]. Monatsschrift Kinderheilkunde: Organ der Deutschen Gesellschaft fur Kinderheilkunde, 2021, 169(1): 62-68. [25] CHUNG B, WAT LCY, WONG V.Febrile seizures in southern Chinese children: incidence and recurrence[J]. Pediatric Neurology, 2006, 34(2): 121-126. [26] TIWARI A, MESHRAM RJ, KUMAR SR.Febrile seizures in children: a review[J]. Cureus, 2022, 14(11): e31509. [27] HACKETT R, PSYCH LHM, MA PB.Febrile seizures in a south Indian district: incidence and associations[J]. Developmental Medicine & Child Neurology, 1997, 39(6): 380-384. [28] WEN QF, WANG F, LIN YF.Analysis of the clinical features and influencing factors of 298 children with their first episode of febrile convulsions[J]. Maternal and Child Health Care of China(中国妇幼保健), 2017, 32(9): 1933-1936. [29] MA XL, SHI S, MA JH, et al.Analysis of the clinical characteristics of 462 cases of children with febrile convulsions[J]. Journal of Ningxia Medical University(宁夏医科大学学报), 2021, 43(10): 1013-1016. [30] CHRISTENSEN KJ, DREIER JW, SKOTTE L, et al.Seasonal variation and risk of febrile seizures: a danish nationwide cohort study[J]. Neuroepidemiology, 2022, 56(2): 138-146. [31] TSUBOI T, OKADA S.Seasonal variation of febrile convulsion in Japan[J]. Acta Neurologica Scandinavica, 1984, 69(5): 285-292. [32] HAN DH, KIM SY, LEE NM, et al.Seasonal distribution of febrile seizure and the relationship with respiratory and enteric viruses in Korean children based on nationwide registry data[J]. Seizure, 2019, 73: 9-13. [33] KEUM HR, LEE SJ, KIM JM, et al.Seasonal trend of viral prevalence and incidence of febrile convulsion: a Korea public health data analysis[J]. Children, 2023, 10(3): 529. [34] YU D, SHAO XL.Research progress on the correlation between children’s vaccination and febrile seizures[J]. Chinese Journal of General Practice(中华全科医学), 2022, 20(11): 1930-1933. [35] MACARTNEY KK, GIDDING HF, TRINH L, et al.Febrile seizures following measles and varicella vaccines in young children in Australia[J]. Vaccine, 2015, 33(11): 1412-1417. [36] HANF M, QUANTIN C, FARRINGTON P, et al.Validation of the French national health insurance information system as a tool in vaccine safety assessment: application to febrile convulsions after pediatric measles/mumps/rubella immunization[J]. Vaccine, 2013, 31(49): 5856-5862. [37] GOLD M, DUGDALE S, WOODMAN RJ, et al.Use of the Australian childhood immunisation register for vaccine safety data linkage[J]. Vaccine, 2010, 28(26): 4308-4311. [38] DENG L, GIDDING H, MACARTNEY K, et al.Postvaccination febrile seizure severity and outcome[J]. Pediatrics, 2019, 143(5): 2018-2120. [39] BARLOW WE, DAVIS RL, GLASSER JW, et al.The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine[J]. The New England Journal of Medicine, 2001, 345(9): 656-661. [40] DUDLEY MZ, SALMON DA, HALSEY NA, et al.The clinician’s vaccine safety resource guide: optimizing prevention of vaccine-preventable diseases across the lifespan[M]. Berlin: Springer, 2018. [41] DI PIETRANTONJ C, RIVETTI A, MARCHIONE P, et al. Vaccines for measles, mumps, rubella,varicella in children[J]. Cochrane Database Syst Rev, 2021, 11: CD004407. [42] SORIOLO N, BENONI R, DALLA VALLE D, et al.Adverse events following measles-mumps-rubella and varicella immunization: a safety profile analysis and comparison of different vaccination schedules based on the italian pharmacovigilance network in the veneto region[J]. Prev Med Rep, 2024, 41: 102711. [43] HUPPERTZ H.Recommendations on the approach when unusual neurological symptoms occur in temporal association with vaccinations in childhood and adolescence[J]. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 2021, 169(1): 62-68. [44] Sciences CFIOOM.Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO working group on vaccine pharmacovigilance[C]. Geneva: WHO/CIOMS, 2012. |
| [1] | CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798. |
| [2] | TAO Xingru, DUAN Yanyan, LIU Xiaoling, LIU Yuemei, ZHANG Shengnan. One Case of Black Hairy Tongue Caused by Doxycycline [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 696-698. |
| [3] | XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong. Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512. |
| [4] | LUO Wen, WU Jing, HE Dake, YANG Rui. One Case of Dermatitis Medicamentosa in a Paediatric Epilepsy Patient Caused by Lacosamide Oral Solution [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 452-455. |
| [5] | JIA Zhichao, HU Siyuan, LI Ruiben, XU Yaqian. Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 324-328. |
| [6] | WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing. Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176. |
| [7] | LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033. |
| [8] | LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan. One case of acute severe pancreatitis caused by pegaspargase and its etiology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077. |
| [9] | CHAO Ying, ZHANG Xuemei, ZHANG Chengjian, WANG Bei. One case of ureterolith combined with gallstone caused by Ceftriaxone sodium for injection in children [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 943-945. |
| [10] | CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, NIE Xiaolu, TAI Jun. Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790. |
| [11] | ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei. Adverse reaction reports of vancomycin in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815. |
| [12] | ZHAO Jie, GAO Ming'e, CHANG Hong, FAN Huixia. Two cases of allergic reactions in children caused by compound polyethylene glycol electrolyte powder [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 816-818. |
| [13] | SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li. Analysis of post-marketing adverse reactions of ametinib [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686. |
| [14] | LIU Tianrui, LI Yao, CHEN Yuxin, LI Hui, GAO Haiyun, YUAN Yuan. Toxicity analysis and safe application of 7 common fungi prone to adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 489-495. |
| [15] | YU Jing, PALATI Reheman, ZHAO Ting, FENG Jirong, SUN Yan, HE Lei. Correlation of the efficacy, safety and plasma concentration of lacosamide in the treatment of children with epilepsy under 4 years of age [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 559-562. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||